Result of Meeting and TVR
Abingdon Health PLC announced that all resolutions proposed at its General Meeting on October 30, 2025, were duly passed, satisfying a condition for completion of its Fundraising. Application has been made for admission of 57,441,821 new Ordinary Shares to trading on AIM, expected to commence around October 31, 2025, at 8:00 a.m. Following admission, the Company's issued ordinary share capital will comprise 251,072,642 Ordinary Shares, representing the total number of voting rights. Executive Chairman Chris Hand purchased 500,000 ordinary shares at 6 pence per share, increasing his holding to 13,678,467 shares, representing 5.4% of the enlarged share capital. Quality and Regulatory Director Candice Vendettuoli purchased 33,333 ordinary shares at 6 pence per share, holding 0.01% of the enlarged share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your ABDX notes
Abingdon Health plc (AIM: ABDX) a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, is pleased to announce that, at the General Meeting held earlier today, the Resolutions set out in the Notice of General Meeting contained in the Circular dated 14 October 2025 were duly passed.
Capitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Company's announcement made at 5:04 p.m. on 13 October 2025, unless the context requires otherwise.
Result of Meeting
Details of the results of the voting at the General Meeting, including the number of votes for and against the Resolutions proposed, and the number of votes withheld, are set out below. The Resolutions were proposed and passed as one ordinary resolution and one special resolution.
| Resolution | For | Against | Withheld | ||
|---|---|---|---|---|---|
| Votes | % of votes cast | Votes | % of votes cast | Votes | |
| 1. Authority to allot shares | 81,408,856 | 99.82 | 144,292 | 0.18 | 23,747 |
| 2. Disapplication of pre-emption rights | 81,247,542 | 99.66 | 273,311 | 0.34 | 56,042 |
The total number of votes received were 163,074,001. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
The passing of the Resolutions is one of the conditions to completion of the Fundraising, and as a result of the votes cast in their favour, that particular condition has been satisfied. Completion of the Fundraising remains conditional upon Admission, which is expected to occur on or around 31 October 2025.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange for admission of the 57,441,821 new Ordinary Shares to trading on AIM ("Admission"). It is expected that Admission will become effective and dealings in the new Ordinary Shares will commence at 8.00 a.m. on or around 31 October 2025.
Following Admission, the Company's issued ordinary share capital will comprise 251,072,642 Ordinary Shares, with no shares held in treasury. Therefore, the number of Total Voting Rights in the Company will be 251,072,642, and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Director and PDMR Shareholdings
Following completion of the Fundraising, the following Directors are interested in the following:
| Director / PDMR | Position | Existing beneficial interest in Ordinary Shares | % of current share capital | New Ordinary Shares subscribed for | Ordinary Shares after Fundraise | % of Enlarged Share Capital |
| Chris Hand | Executive Chairman | 13,178,467 | 6.8 | 500,000 | 13,678,467 | 5.4% |
| Candice Vendettuoli | Quality and Regulatory Director | - | - | 33,333 | 33,333 | 0.01% |
| a) | Name | Abingdon Health plc | ||||
| b) | LEI | 213800XFI4WV3FBILO20 | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.025 pence each | ||||
| Identification code | GB00BLF79J41 | |||||
| b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| 6 pence per share | 500,000 | |||||
| d) | Aggregated information | |||||
| - Aggregated volume | 500,000 | |||||
| - Price | 6 pence per share | |||||
| e) | Date of the transaction | 30 October 2025 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Candice Vendettuoli | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Quality and Regulatory Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| a) | Name | Abingdon Health plc | ||||
| b) | LEI | 213800XFI4WV3FBILO20 | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.025 pence each | ||||
| Identification code | GB00BLF79J41 | |||||
| b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| 6 pence per share | 33,333 | |||||
| d) | Aggregated information | |||||
| - Aggregated volume | 33,333 | |||||
| - Price | 6 pence per share | |||||
| e) | Date of the transaction | 30 October 2025 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.